![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preclinical Pharmacokinetics, Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium (D.R., P.A., J.V.H., A.W., J.N., C.V.L., J.H., G.M., W.M.); and Preclinical Drug Evaluation–Drug Metabolism, Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersey (C.S., J.S.)
Fresh human hepatocytes are still considered as the "gold standard" to screen in vitro for cytochrome P450 (P450) induction. However, sparse availability of good quality human liver tissue for research purposes and the demand for standardized cell populations, together with the need for proper storage of the cells not immediately required, have resulted in the development of cryopreservation techniques that provide adequate viability and plateability of hepatocytes after thawing. This study aimed at validating cryopreserved human hepatocytes as a model to investigate P450 induction. Cryopreserved cells from four different donors were plated and cultured for 48 h, followed by incubation in the presence of typical P450 inducers. During the experiments, quality of the cultured cells was monitored both physiologically and morphologically. Concomitantly, the activity of CYP1A2, 2B6, 2C9, 2E1, and 3A4 was measured together with their mRNA and protein expression. Determination of CYP1A2, 2B6, 2C9, 2E1, and 3A4 activity in control versus prototypical inducer-treated hepatocytes revealed a maximal significant mean 11.6-, 2.8-, 1.9-, 1.5-, and 9.0-fold induction over their basal expression, respectively. Protein expression analysis of these P450s confirmed these results. Moreover, a mean 44.9-, 3.5-, 3.2-, and 13.8-fold induction of CYP1A2, 2B6, 2C9, and 3A4 mRNA was observed. Our data demonstrate that cryopreserved human hepatocytes are a valuable tool to study the induction of CYP1A2, 2B6, 2C9, 2E1, and 3A4.
This article has been cited by other articles:
|
|
 |
|
  V. Chu, H. J. Einolf, R. Evers, G. Kumar, D. Moore, S. Ripp, J. Silva, V. Sinha, M. Sinz, and A. Skerjanec In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective Drug Metab. Dispos., July 1, 2009; 37(7): 1339 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Harmsen, A. S. Koster, J. H. Beijnen, J. H. M. Schellens, and I. Meijerman Comparison of Two Immortalized Human Cell Lines to Study Nuclear Receptor-Mediated CYP3A4 Induction Drug Metab. Dispos., June 1, 2008; 36(6): 1166 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Huang, J. M. Strong, L. Zhang, K. S. Reynolds, S. Nallani, R. Temple, S. Abraham, S. A. Habet, R. K. Baweja, G. J. Burckart, et al. New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process J. Clin. Pharmacol., June 1, 2008; 48(6): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhu, J. Puglisi, D. Connors, J. Stewart, J. Herbst, A. Marino, M. Sinz, J. O'Connell, M. Banks, K. Dickinson, et al. Use of Cryopreserved Transiently Transfected Cells in High-Throughput Pregnane X Receptor Transactivation Assay J Biomol Screen, March 1, 2007; 12(2): 248 - 254. [Abstract] [PDF]
|
|
|
|
|
|
L. Richert, M. J. Liguori, C. Abadie, B. Heyd, G. Mantion, N. Halkic, and J. F. Waring GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING Drug Metab. Dispos., May 1, 2006; 34(5): 870 - 879. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
